La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MiMedx Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MiMedx Group..

MiMedx Group (NASDAQ:MDXG) Azioni, Catena delle Opzioni

MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

MIMEDX GROUP INC

MiMedx Group Inc

MiMedx Group Non-GAAP EPS of $0.07 beats by $0.03, revenue of $84M beats by $0.98M

MiMedx Group ( ($MDXG) ) has provided an announcement. MiMedx Group reported a 3% increase in net sales for Q3 2024, reaching $84 million, driven b...

MiMedx Group Reports 3% Sales Increase in Q3 2024

MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript

MiMedx Group Inc. ( ($MDXG) ) has realeased its Q3 earnings. Here is a breakdown of the information MiMedx Group Inc. presented to its investors. M...

MiMedx Group Inc. Reports Q3 2024 Financial Results

MiMedx (MDXG) provided the following update on the Local Coverage Determinations, LCDs, regarding "Skin Substitute Grafts/Cellular and Tissue-Based...

MiMedx provided update on LCDs regarding skin substitute

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Disney (DIS) reported better-than-expe...

Disney reports Q4 beat, Capri-Tapestry call off deal: Morning Buzz

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on MiMedx Group (MDXG – Research Report) today. The company's shares closed yester...

Craig-Hallum Reaffirms Their Buy Rating on MiMedx Group (MDXG)

In a report released today, Carl Byrnes from Northland Securities reiterated a Buy rating on MiMedx Group (MDXG – Research Report), with a price ta...

Northland Securities Sticks to Their Buy Rating for MiMedx Group (MDXG)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) and M...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG)

Northland Securities analyst Carl Byrnes maintained a Buy rating on MiMedx Group (MDXG – Research Report) today and set a price target of $12.00. T...

Northland Securities Sticks to Its Buy Rating for MiMedx Group (MDXG)

AAPL

AMZN

BILI

BLNK

CBRL

CPRI

CRKN

CSCO

GAMB

HIMS

HNHAF

HNHPF

MDXG

NVDA

OMER

PLUG

PZZA

SFTBF

SFTBY

SPOT

Press Releases

DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT

News

Health Care

MIMEDX to Participate in Upcoming Investor Conferences

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'

EX-MiMEDX EMPLOYEES ALLEGE  MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

General

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

Earnings

MIMEDX Announces Third Quarter 2024 Operating and Financial Results

MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Bicara Therapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

CareDx

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

89bio

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Comments

MiMedx Group

MiMedx Group (MDXG) Opzioni

MiMedx Group (NASDAQ:MDXG) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO